

Correction: PARP-1 inhibitor modulate β -catenin signaling to enhance cisplatin sensitivity in cancer cervix

Minakshi Mann¹, Sachin Kumar¹, Shyam S. Chauhan², Neerja Bhatla³, Sunesh Kumar³, Sameer Bakhshi¹, Ritu Gupta⁴, Ashok Sharma² and Lalit Kumar¹

¹Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

²Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India

³Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India

⁴Laboratory Oncology Unit, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi, India

Published: July 30, 2019

Copyright: Mann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Dr. Ashok Sharma has been named as co-corresponding author on this paper, and has been moved from third place to second-to-last author in the listing.

Original article: 2019; 10:4262–4275. <https://doi.org/10.18632/oncotarget.27008>